Lumos Diagnostics Holdings (ASX:LDX) Short-Term Debt: A$1.65 Mil (As of Dec. 2025)


What is Lumos Diagnostics Holdings Short-Term Debt?

Lumos Diagnostics Holdings ASX:LDX -6.67% Short-Term Debt is A$1.65 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Lumos Diagnostics Holdings's Short-Term Debt for the quarter that ended in Dec. 2025 was A$1.65 Mil.

Lumos Diagnostics Holdings's quarterly Short-Term Debt declined from Dec. 2024 (A$1.65 Mil) to Jun. 2025 (A$0.00 Mil) but then increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$1.65 Mil).

Lumos Diagnostics Holdings's annual Short-Term Debt declined from Jun. 2023 (A$2.01 Mil) to Jun. 2024 (A$0.00 Mil) but then stayed the same from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Lumos Diagnostics Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Lumos Diagnostics Holdings Short-Term Debt Related Terms

Lumos Diagnostics Holdings Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Short-Term Debt Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Short-Term Debt
0.00 2.01 0.00 0.00

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.35 0.00 1.65 0.00 1.65
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$1.65 Mil mean?
Lumos Diagnostics Holdings (ASX:LDX) has a Short-Term Debt of A$1.65 Mil as of Dec. 2025.
Is Lumos Diagnostics Holdings' Short-Term Debt too high?
Lumos Diagnostics Holdings' current Short-Term Debt is A$1.65 Mil.
How does Lumos Diagnostics Holdings' Short-Term Debt compare to ABT and SYK?
Lumos Diagnostics Holdings' Short-Term Debt of A$1.65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Lumos Diagnostics Holdings's current Short-Term Debt is A$1.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.10 — trading 390% above its estimated fair value. The current Short-Term Debt is A$1.65 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Short-Term Debt is A$1.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.